Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biosite and UK-based Oxford Genome Sciences are to collaborate on the evaluation of protein-based disease markers for colorectal cancer. The markers could be used for the development of blood-based diagnostic products aimed at expanding personalized therapeutic options for colorectal cancer.
Subscribe to our email newsletter
In particular, these blood-based diagnostics would be designed to enable the early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate therapeutic option.
Today, the fecal occult blood test and colonoscopy are the most frequently used screening and diagnostic methods for colorectal cancer, which has a 30 to 40% recurrence rate within an average of 18 months after primary diagnosis.
Oxford Genome Sciences (OGeS) has developed a database that integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases.
Under the terms of the collaboration, OGeS will identify at least 25 proteins discovered in blood and tissue samples from relapsing colorectal cancer patients and Biosite will have the rights to develop blood-based diagnostic tests using one or more of those biomarkers. Financial terms of the agreement were not disclosed.
“We are increasingly interested in studying selected areas of cancer that can benefit from rapid, effective, non-invasive diagnostic technologies,” said Kim Blickenstaff, Biosite’s chairman and CEO. “This collaboration expands our research aimed at evaluation of diagnostic tools for relapsing colorectal cancer by providing us with access to high quality validation of potentially valuable protein biomarkers.”